Figures 1 and 2 should be read with the footnotes that contain important general information and considerations for special populations.

**Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2017**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>19–21 years</th>
<th>22–26 years</th>
<th>27–59 years</th>
<th>60–64 years</th>
<th>≥ 65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza(^1)</td>
<td></td>
<td></td>
<td>1 dose annually</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td/Tdap(^2)</td>
<td></td>
<td></td>
<td></td>
<td>Substitute Tdap for Td once, then Td booster every 10 yrs</td>
<td></td>
</tr>
<tr>
<td>MMR(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR(^4)</td>
<td></td>
<td></td>
<td>2 doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HZV(^5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 dose</td>
</tr>
<tr>
<td>HPV–Female(^6)</td>
<td></td>
<td></td>
<td>3 doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV–Male(^6)</td>
<td></td>
<td></td>
<td>3 doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13(^7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 dose</td>
</tr>
<tr>
<td>PPSV23(^7)</td>
<td></td>
<td></td>
<td></td>
<td>1 or 2 doses depending on indication</td>
<td>1 dose</td>
</tr>
<tr>
<td>HepA(^8)</td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB(^9)</td>
<td></td>
<td></td>
<td>3 doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenACWY or MPSV4(^10)</td>
<td></td>
<td></td>
<td>1 or more doses depending on indication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB(^10)</td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib(^11)</td>
<td></td>
<td></td>
<td>1 or 3 doses depending on indication</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection**
- **Recommended for adults with additional medical conditions or other indications**
- **No recommendation**
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Pregnancy¹⁻⁶,¹¹</th>
<th>Immuno-compromised (excluding HIV infection)³⁻⁷,¹¹</th>
<th>HIV infection CD4+ count (cells/μL)²⁻⁷,⁹⁻¹¹</th>
<th>Asplenia, persistent complement deficiencies⁷,¹⁰,¹¹</th>
<th>Kidney failure, end-stage renal disease, on hemodialysis⁷⁻⁹</th>
<th>Heart or lung disease, chronic alcoholism⁷</th>
<th>Chronic liver disease⁷⁻⁹</th>
<th>Diabetes⁷⁻⁹</th>
<th>Healthcare personnel¹⁻⁴,⁹</th>
<th>Men who have sex with men⁶,⁸,⁹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td/Tdap²</td>
<td>1 dose Tdap each pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR³</td>
<td>contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR⁴</td>
<td>contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HZV⁵</td>
<td>contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV–Female⁶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV–Male⁶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepA⁸</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
</tr>
<tr>
<td>HepB⁹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 doses</td>
</tr>
<tr>
<td>MenACWY or MPSV4¹⁰</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 or more doses depending on indication</td>
</tr>
<tr>
<td>MenB¹⁰</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
</tr>
<tr>
<td>Hib¹¹</td>
<td>3 doses post-HSCT recipients only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 dose</td>
</tr>
</tbody>
</table>

Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with additional medical conditions or other indications

Contraindicated

No recommendation
1. Influenza vaccination

**General information**
- All persons aged 6 months or older who do not have a contraindication should receive annual influenza vaccination with an age-appropriate formulation of inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV).
- In addition to standard-dose IIV, available options for adults in specific age groups include: high-dose or adjuvanted IIV for adults aged 65 years or older, intradermal IIV for adults aged 18 through 64 years, and RIV for adults aged 18 years or older.
- Notes: Live attenuated influenza vaccine (LAIV) should not be used during the 2016–2017 influenza season. A list of currently available influenza vaccines is available at www.cdc.gov/flu/protect/vaccine/vaccines.htm.

**Special populations**
- Pregnant women who do not have evidence of immunity to rubella should receive 1 dose of MMR upon completion or termination of pregnancy and before discharge from the healthcare facility; non-pregnant women of childbearing age without evidence of rubella immunity should receive 1 dose of MMR.
- Adults with primary or acquired immunodeficiency including malignant conditions affecting the bone marrow or lymphatic system, systemic immunosuppressive therapy, or cellular immunodeficiency should not receive MMR.
- Adults with human immunodeficiency virus (HIV) infection and CD4+ T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have evidence of measles, mumps, or rubella immunity should receive 2 doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ T-lymphocyte count <200 cells/μl should not receive MMR.
- Adults who work in healthcare facilities should receive 2 doses of MMR at least 28 days apart; healthcare personnel born before 1957 who are unvaccinated or lack laboratory evidence of measles, mumps, or rubella immunity, or laboratory confirmation of disease should be considered for vaccination with 2 doses of MMR at least 28 days apart for measles or mumps, or 1 dose of MMR for rubella.
- Adults who are students in postsecondary educational institutions or plan to travel internationally should receive 2 doses of MMR at least 28 days apart.
- Adults who received inactivated (killed) measles vaccine or measles vaccine of unknown type during years 1963–1967 should be revaccinated with 1 or 2 doses of MMR.
- Adults who were vaccinated between 1979 with either inactivated mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection, e.g., work in a healthcare facility, should be considered for revaccination with 2 doses of MMR at least 28 days apart.

2. Tetanus, diphtheria, and acellular pertussis vaccination

**General information**
- Adults who have not received tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap) or for whom pertussis vaccination status is unknown should receive 1 dose of Tdap followed by a tetanus and diphtheria toxoids (Td) booster every 10 years. Tdap should be administered regardless of when a tetanus or diphtheria toxoid-containing vaccine was last received.
- Adults with an unknown or incomplete history of a 3-dose primary series with tetanus and diphtheria toxoid-containing vaccines should complete the primary series that includes 1 dose of Tdap. Unvaccinated adults should receive the first 2 doses at least 4 weeks apart and the third dose 6–12 months after the second dose.
- Notes: Information on the use of Td or Tdap as tetanus prophylaxis in wound management is available at www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm.

**Special populations**
- Pregnant women should receive 1 dose of Tdap during each pregnancy, preferably during the early part of gestational weeks 27–36, regardless of prior history of receiving Tdap.

3. Measles, mumps, and rubella vaccination

**General information**
- Adults born in 1957 or later without acceptable evidence of immunity to measles, mumps, or rubella (defined below) should receive 1 dose of measles, mumps, and rubella vaccine (MMR) unless they have a medical contraindication to the vaccine, e.g., pregnancy or severe immunodeficiency.
- Notes: Acceptable evidence of immunity to measles, mumps, or rubella in adults is: born before 1957, documentation of receipt of MMR, or laboratory evidence of immunity or disease. Documentation of healthcare provider-diagnosed disease without laboratory confirmation is not acceptable evidence of immunity.

**Special populations**
- Pregnant women who do not have evidence of immunity to rubella should receive 1 dose of MMR upon completion or termination of pregnancy and before discharge from the healthcare facility; non-pregnant women of childbearing age without evidence of rubella immunity should receive 1 dose of MMR.
- Adults with primary or acquired immunodeficiency including malignant conditions affecting the bone marrow or lymphatic system, systemic immunosuppressive therapy, or cellular immunodeficiency should not receive MMR.
- Adults with human immunodeficiency virus (HIV) infection and CD4+ T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have evidence of measles, mumps, or rubella immunity should receive 2 doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ T-lymphocyte count <200 cells/μl should not receive MMR.
- Adults who work in healthcare facilities should receive 2 doses of MMR at least 28 days apart; healthcare personnel born before 1957 who are unvaccinated or lack laboratory evidence of measles, mumps, or rubella immunity, or laboratory confirmation of disease should be considered for vaccination with 2 doses of MMR at least 28 days apart for measles or mumps, or 1 dose of MMR for rubella.
- Adults who are students in postsecondary educational institutions or plan to travel internationally should receive 2 doses of MMR at least 28 days apart.
- Adults who received inactivated (killed) measles vaccine or measles vaccine of unknown type during years 1963–1967 should be revaccinated with 1 or 2 doses of MMR.
- Adults who were vaccinated between 1979 with either inactivated mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection, e.g., work in a healthcare facility, should be considered for revaccination with 2 doses of MMR at least 28 days apart.

4. Varicella vaccination

**General information**
- Adults without evidence of immunity to varicella (defined below) should receive 2 doses at least 4 weeks apart; varicella vaccine (VAR) 4–8 weeks apart, or a second dose if they have received only 1 dose.
- Persons without evidence of immunity for whom VAR should be emphasized are: adults who have close contact with persons at high risk for serious complications, e.g., healthcare personnel and household contacts of immunocompromised persons; adults who live or work in an environment in which transmission of varicella zoster virus is likely, e.g., teachers, childcare workers, and residents and staff in institutional settings; adults who live or work in environments in which varicella transmission has been reported, e.g., college students residing in dormitories or military personnel; non-pregnant women of childbearing age, adolescents and adults living in households with children, and international travelers.
- Notes: Evidence of immunity to varicella in adults: U.S.-born before 1980 (for pregnant women and healthcare personnel, U.S.-born before 1980 is not considered evidence of immunity); documentation of 2 doses of VAR at least 4 weeks apart; history of varicella or herpes zoster diagnosis or verification of varicella or herpes zoster disease by a healthcare provider; or laboratory evidence of immunity or disease.

**Special populations**
- Pregnant women should be assessed for evidence of varicella immunity. Pregnant women who do not have evidence of immunity should receive the first dose of VAR upon completion or termination of pregnancy and before discharge from the healthcare facility, and the second dose 4–8 weeks after the first dose.
- Healthcare institutions should assess and ensure that all healthcare personnel have evidence of immunity to varicella.
- Adults with malignant conditions, including those that affect the bone marrow or lymphatic system or who receive systemic immunosuppressive therapy, should not receive VAR.
- Adults with human immunodeficiency virus (HIV) infection and CD4+ T-lymphocyte count ≥200 cells/μl may receive 2 doses of VAR 3 months apart. Adults with CD4+ T-lymphocyte count <200 cells/μl should not receive VAR.

5. Herpes zoster vaccination

**General information**
- Adults aged 60 years or older should receive 1 dose of herpes zoster vaccine (HZV), regardless of whether they had a prior episode of herpes zoster.

**Special populations**
- Adults aged 60 years or older with chronic medical conditions may receive HZV unless they have a medical contraindication, e.g., pregnancy or severe immunodeficiency.
- Adults with malignant conditions, including those that affect the bone marrow or lymphatic system or who receive systemic immunosuppressive therapy, should not receive HZV.
- Adults with human immunodeficiency virus (HIV) infection and CD4+ T-lymphocyte count <200 cells/μl should not receive HZV.

6. Human papillomavirus vaccination

**General information**
- Adult females through age 26 years and adult males through age 21 years who have not received any human papillomavirus (HPV) vaccine should receive a 3-dose series of HPV vaccine at 0, 1–2, and 6 months. Males aged 22 through 26 years may be vaccinated with a 3-dose series of HPV vaccine at 0, 1–2, and 6 months.
- Adult females through age 26 years and adult males through age 21 years (and males aged 22 through 26 years who may receive HPV vaccination) who initiated the HPV vaccination series before age 15 years and received 2 doses at least 5 months apart are considered adequately vaccinated and do not need an additional dose of HPV vaccine.
- Adult females through age 26 years and adult males through age 21 years (and males aged 22 through 26 years who may receive HPV vaccination) who initiated the HPV vaccination series before age 15 years and received only 1 dose, or 2 doses less than 5 months apart, are not considered adequately vaccinated and should receive 1 additional dose of HPV vaccine.
- Notes: HPV vaccination is routinely recommended for children at age 11 or 12 years. For adults who had initiated but did not complete the HPV vaccination series, consider their age at first HPV vaccination (described above) and other factors (described below) to determine if they have been adequately vaccinated.

**Special populations**
- Men who have sex with men through age 26 years who have not received any HPV vaccine should receive a 3-dose series of HPV vaccine at 0, 1–2, and 6 months.
- Adult females and males through age 26 years with immunocompromising conditions (described below), including those with human immunodeficiency virus (HIV) infection, should receive a 3-dose series of HPV vaccine at 0, 1–2, and 6 months.
- Pregnant women are not recommended to receive HPV vaccine, although there is no evidence that the vaccine poses harm. If a woman is found to be pregnant after initiating the HPV vaccination series, delay the remaining doses until after the pregnancy. No other intervention is needed. Pregnancy testing is not needed before administering HPV vaccine.
- Notes: Immunocompromising conditions for which a 3-dose series of HPV vaccine is indicated are primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity, e.g., B-lymphocyte antibody deficiencies, complete or partial T-lymphocyte defects, HIV infection, malignant neoplasm, transplantation, autoimmune disease, and immunosuppressive therapy.
7. Pneumococcal vaccination

General information
- Adults who are immunocompetent and aged 65 years or older should receive 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 1 year after PCV13.
- Notes: Adults are recommended to receive 1 dose of PCV13 and 1, 2, or 3 doses of PPSV23 depending on indication. When both PCV13 and PPSV23 are indicated, PCV13 should be administered first; PCV13 and PPSV23 should not be administered during the same visit. If PPSV23 has previously been administered, PCV13 should be administered at least 1 year after PPSV23. If more doses of PCV13 are indicated, the interval between PPSV23 doses should be at least 5 years. Supplemental information on pneumococcal vaccine timing for adults aged 65 years or older and adults aged 19 years or older at high risk for pneumococcal disease (described below) is available at www.cdc.gov/vaccines/vpd-vac/pneumonia/default.htm. Adults with anatomical or functional asplenia or persistent complement deficiencies should receive a HepA series: have chronic liver disease, receive clotting factor concentrates, men who have sex with men, use injection or non-injection drugs, or work with hepatitis A virus-infected primates or in a hepatitis A research laboratory setting.
- Adults who travel in countries with high or intermediate levels of endemic hepatitis A infection or anticipate close personal contact with an international adoptee, e.g., reside in the same household or regularly babysit, from a country with high or intermediate level of endemic hepatitis A infection within the first 60 days of arrival in the United States should receive a HepA series.

Special populations
- Adults with any of the following indications should receive a HepA series: have chronic liver disease, receive clotting factor concentrates, men who have sex with men, use injection or non-injection drugs, or work with hepatitis A virus-infected primates or in a hepatitis A research laboratory setting.
- Adults who travel in countries with high or intermediate levels of endemic hepatitis A infection or anticipate close personal contact with an international adoptee, e.g., reside in the same household or regularly babysit, from a country with high or intermediate level of endemic hepatitis A infection within the first 60 days of arrival in the United States should receive a HepA series.

9. Hepatitis B vaccination

General information
- Adults who seek protection from hepatitis B virus infection may receive a 3-dose series of single-antigen-licensed Haemophilus b (Hib) vaccine (Engerix-B, Recombivax HB) at 0, 1, and 6 months. Adults may also receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) (Twintix) at 0, 1, and 6 months. Acknowledgment of a specific risk factor by those who seek protection is not needed.

Special populations
- Adults at risk for hepatitis B virus infection by sexual exposure should receive a HepB series, including sex partners of hepatitis B surface antigen (HBsAg)-positive persons, sexually active persons who are not in a monogamous relationship, persons seeking evaluation or treatment for a sexually transmitted infection, and men who have sex with men (MSM).
- Adults at risk for hepatitis B virus infection by percutaneous or mucosal exposure to blood should receive a HepB series, including adults who are recent or current users of injection drugs, household contacts of HBsAg-positive persons, residents and staff of facilities for developmentally disabled persons, incarcerated, health care, and public safety workers at risk for exposure to blood or blood-contaminated body fluids, younger than age 60 years with diabetes mellitus, and age 60 years or older with diabetes mellitus at the discretion of the treating clinician.
- Adults with chronic liver disease including, but not limited to, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than twice the upper limit of normal should receive a HepB series.
- Adults with end-stage renal disease including those on pre-dialysis care, hemodialysis, peritoneal dialysis, and home dialysis should receive a HepB series. Adults on hemodialysis should receive a 3-dose series of 40 μg Recombivax HB at 0, 1, and 6 months or a 4-dose series of 40 μg Engerix-B at 0, 1, 2, and 6 months.
- Adults with hepatitis C virus infection should receive a HepB series.
- Pregnant women who are at risk for hepatitis B virus infection during pregnancy, e.g., having more than one sex partner during the previous six months, been evaluated or treated for a sexually transmitted infection, recent or current injection drug use, or had an HBsAg-positive sex partner should receive a HepB series.
- International travelers to regions with high or intermediate levels of endemic hepatitis B virus infection should receive a HepB series.
- Adults in the following settings are assumed to be at risk for hepatitis B virus infection and should receive a HepB series: sexually transmitted disease treatment facilities, HIV testing and treatment facilities, facilities providing drug-abuse treatment and prevention services, healthcare settings targeting services to persons who inject drugs, correctional facilities, healthcare settings targeting services to MSM, hemodialysis facilities and end-stage renal disease programs, and institutions and nonresidential day care facilities for developmentally disabled persons.

10. Meningococcal vaccination

Special populations
- Adults with anatomical or functional asplenia or persistent complement deficiency should receive a 2-dose primary series of serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) at least 2 months apart and revaccinate every 5 years. They should also receive a series of serogroup B meningococcal vaccine (MenB) with either a 2-dose series of serogroup B vaccine (4C) at least 1 month apart or a 3-dose series of MenB-FHbp (Trumenba) at 0, 1–2, and 6 months.
- Adults with human immunodeficiency virus (HIV) infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY at least 2 months apart and revaccinate every 5 years. Those who have previously received 1 dose of MenACWY should receive a second dose at least 2 months after the first dose. Adults with HIV infection are not routinely recommended to receive MenB because meningococcal disease in this population is caused primarily by serogroups C, W, and Y.
- Microbiologists who are routinely exposed to isolates of Neisseria meningitidis should receive a 1 dose of MenACWY and revaccinate every 5 years if the risk for infection remains, and either a 2-dose series of MenB-4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1–2, and 6 months.
- Adults at risk because of a meningococcal disease outbreak should receive 1 dose of MenACWY if the outbreak is attributable to serogroups C, W, or Y, or either a 2-dose series of MenB-4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1–2, and 6 months if the outbreak is attributable to serogroup B.
- Adults with a medical or life history in countries with hyperendemic or epidemic meningococcal disease should receive 1 dose of MenACWY and revaccinate every 5 years if the risk for infection remains. MenB is not routinely indicated because meningococcal disease in these countries is generally serogroup B.
- Military recruits should receive 1 dose of MenACWY and revaccinate every 5 years if the increased risk for infection remains.
- First-year college students aged 21 years or younger who live in residence halls should receive 1 dose of MenACWY if they have not received MenACWY or MenB before or an additional dose of MenACWY if they have received MenACWY or MenB before.
- Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) who are healthy and not at increased risk for serogroup B meningococcal disease (described above) may receive either a 2-dose series of MenACWY or MenB at 0 and 6 months or 0, 1–2, and 6 months if the outbreak is attributable to serogroup B.
- Adults aged 16 years or older who have not previously received serogroups A, C, W, and Y meningococcal vaccine and need only 1 dose of MenACWY may receive a 3-dose series of MenACWY at ages 16 years or older.
- Pregnant women who are at risk for meningococcal disease should receive 1 dose of MenACWY at least 2 months before delivery.

11. Haemophilus influenzae type b vaccination

Special populations
- Adults who have anatomic or functional asplenia or sickle cell disease, or are undergoing elective splenectomy should receive 1 dose of Haemophilus influenzae type b (Hib) vaccine if they have not previously received Hib. Hib should be administered at least 14 days before splenectomy.
- Adults with a hematopoietic stem cell transplant (HSCT) should receive 3 doses of Hib at least 4 weeks intervals 6–12 months after transplant regardless of their Hib history.
- Notes: Hib is not routinely recommended for adults with human immunodeficiency virus infection because their risk for Haemophilus influenzae type b infection is low.
The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions that increase chances of a serious adverse reaction in vaccine recipients and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine recipient. For a person with a severe allergy to latex, e.g., anaphylaxis, vaccines supplied in vials or syringes that contain natural rubber latex should not be administered unless the benefit of vaccination clearly outweighs the risk for a potential allergic reaction. For latex allergies other than anaphylaxis, vaccines supplied in vials or syringes that contain dry, natural rubber or natural rubber latex may be administered.

### Contraindications and precautions for vaccines routinely recommended for adults

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Contraindications</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>All vaccines routinely recommended for adults</td>
<td>Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component</td>
<td>Moderate or severe acute illness with or without fever</td>
</tr>
</tbody>
</table>

#### Additional contraindications and precautions for vaccines routinely recommended for adults

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Additional Contraindications</th>
<th>Additional Precautions</th>
</tr>
</thead>
</table>
| IIV^1  | • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, human immunodeficiency virus (HIV) infection with severe immunocompromise | • History of Guillain–Barré Syndrome within 6 weeks after previous influenza vaccination  
• History of Guillain–Barré Syndrome within 6 weeks after previous dose of tetanus toxoid-containing vaccine  
• Guillain–Barré Syndrome within 6 weeks after a previous dose of tetanus or diphtheria toxoid or acellular pertussis  
• Pregnancy |
| RIV^1  | • LAIV should not be used during 2016–2017 influenza season | • LAIV should not be used during 2016–2017 influenza season |
| LAIV^2 | • For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, or prolonged seizures, not attributable to another identifiable cause within 7 days of administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular pertussis | • Guillain–Barré Syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine  
• History of a previous vaccine-related fever or reaction |
| Tdap/Td | • For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, or prolonged seizures, not attributable to another identifiable cause within 7 days of administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular pertussis | • Guillain–Barré Syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine  
• For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy (until a treatment regimen has been established and the condition has stabilized) |
| MMR^2  | • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, human immunodeficiency virus (HIV) infection with severe immunocompromise  
• Pregnancy | • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)^4  
• History of thrombocytopenia or thrombocytopenia purpura  
• Need for tuberculin skin testing^5 |
| VAR^6  | • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, human immunodeficiency virus (HIV) infection with severe immunocompromise  
• Pregnancy | • Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)^4  
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination) |
| HZV^7  | • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, human immunodeficiency virus (HIV) infection with severe immunocompromise  
• Pregnancy | • Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination) |
| HPV vaccine | | • Pregnancy |
| PCV13  | • Severe allergic reaction to any vaccine containing diphtheria toxoid | |

---

2. MMR may be administered together with VAR or HZV on the same day, if not administered on the same day, separate live vaccines by at least 28 days.
5. Measles vaccination may temporarily suppress tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.

---

**Acronyms of vaccines recommended for adults**

HepA = hepatitis A vaccine  
HepA-HepB = hepatitis A and hepatitis B vaccines  
HepB = hepatitis B vaccine  
Hib = Haemophilus influenzae type b conjugate vaccine  
HPV vaccine = human papillomavirus vaccine  
HIV = inactivated influenza vaccine  
IIV = inactivated influenza vaccine  
LAIV = live attenuated influenza vaccine  
MenACWY = serogroups A, C, W, and Y meningococcal conjugate vaccine  
MenB = serogroup B meningococcal vaccine  
MMR = measles, mumps, and rubella vaccine  
MPSV4 = serogroups A, C, W, and Y meningococcal polysaccharide vaccine  
PCCV13 = 13-valent pneumococcal conjugate vaccine  
PPSV23 = 23-valent pneumococcal polysaccharide vaccine  
RIV = recombinant influenza vaccine  
Td = tetanus and diphtheria toxoids  
Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine  
VAR = varicella vaccine

---

CS270457-A